Raras
Buscar doenças, sintomas, genes...
Alteração da proteína N-glicosilação
ORPHA:309347CID-11 · 5C54.0DOENÇA RARA

É uma doença causada por um defeito na glicosilação N-ligada das proteínas.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma doença causada por um defeito na glicosilação N-ligada das proteínas.

Publicações científicas
1 artigos
Último publicado: 2017 Apr
Medicamentos
2 registrados
EPALRESTAT, ACETAZOLAMIDE

Tem tratamento?

2 medicamentos registrados
Ver detalhes, fases e interações →
EPALRESTATACETAZOLAMIDE
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
74 sintomas
🦴
Ossos e articulações
64 sintomas
😀
Face
38 sintomas
🫃
Digestivo
32 sintomas
📏
Crescimento
30 sintomas
👁️
Olhos
28 sintomas

+ 243 sintomas em outras categorias

Características mais comuns

Traços faciais grosseiros
Hepatite crônica
Quimiotaxia de neutrófilos prejudicada
Perda da camada fotorreceptora na OCT macular
Concentração elevada de alanina aminotransferase circulante
Enrugamento prematuro da pele
646sintomas
Sem dados (646)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 646 características clínicas mais associadas, ordenadas por frequência.

Traços faciais grosseirosCoarse facial features
Hepatite crônicaChronic hepatitis
Quimiotaxia de neutrófilos prejudicadaImpaired neutrophil chemotaxis
Perda da camada fotorreceptora na OCT macularPhotoreceptor layer loss on macular OCT
Concentração elevada de alanina aminotransferase circulanteElevated circulating alanine aminotransferase concentration

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa9desde 2017
Total histórico1PubMed
Últimos 10 anos1publicações
Pico20171 papers
Linha do tempo
20202017Hoje · 2026🧪 2018Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

24 genes identificados com associação a esta condição.

ALG3Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1D

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG3-congenital disorder of glycosylation
HGNC:23056UniProt:Q92685
MOGSMannosyl-oligosaccharide glucosidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

In the context of N-glycan degradation, cleaves the distal alpha 1,2-linked glucose residue from the Glc(3)Man(9)GlcNAc(2) oligosaccharide precursor in a highly specific manner

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Maturation of spike proteinMaturation of spike proteinRegulation of CDH1 posttranslational processing and trafficking to plasma membraneN-glycan trimming in the ER and Calnexin/Calreticulin cycle
MECANISMO DE DOENÇA

Type IIb congenital disorder of glycosylation

Characterized by marked generalized hypotonia and hypomotility of the neonate, dysmorphic features, including a prominent occiput, short palpebral fissures, retrognathia, high arched palate, generalized edema, and hypoplastic genitalia. Symptoms of the infant included hepatomegaly, hypoventilation, feeding problems and seizures. The clinical course was progressive and the infant did not survive more than a few months.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
86.2 TPM
Baço
83.4 TPM
Pituitária
75.9 TPM
Fibroblastos
75.1 TPM
Próstata
74.9 TPM
OUTRAS DOENÇAS (1)
MOGS-congenital disorder of glycosylation
HGNC:24862UniProt:Q13724
ALG9Alpha-1,2-mannosyltransferase ALG9Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses.

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (3)
ALG9-congenital disorder of glycosylationGillessen-Kaesbach-Nishimura syndromeautosomal dominant polycystic kidney disease
HGNC:15672UniProt:Q9H6U8
DPAGT1UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen su

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1J

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
50.3 TPM
Cervix Endocervix
43.7 TPM
Útero
39.0 TPM
Fallopian Tube
38.1 TPM
Próstata
37.8 TPM
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 13DPAGT1-congenital disorder of glycosylationobsolete congenital myasthenic syndromes with glycosylation defect
HGNC:2995UniProt:Q9H3H5
STT3BDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3BDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalytic subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation (PubMed:19167329, PubMed:31296534, PubMed:31831667, PubMed:39509507). N-glycosylation occurs cotranslationally and the complex associates with the Sec61 com

LOCALIZAÇÃO

Endoplasmic reticulumEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Maturation of spike proteinAsparagine N-linked glycosylationPD-L1(CD274) glycosylation and translocation to plasma membraneMaturation of DENV proteinsRegulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1X

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
168.0 TPM
Fibroblastos
124.1 TPM
Testículo
119.3 TPM
Linfócitos
112.5 TPM
Aorta
99.0 TPM
OUTRAS DOENÇAS (1)
STT3B-congenital disorder of glycosylation
HGNC:30611UniProt:Q8TCJ2
PGM1Phosphoglucomutase-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible isomerization of alpha-D-glucose 1-phosphate to alpha-D-glucose 6-phosphate (PubMed:15378030, PubMed:25288802). The mechanism proceeds via the intermediate compound alpha-D-glucose 1,6-bisphosphate (Probable) (PubMed:25288802). This enzyme participates in both the breakdown and synthesis of glucose (PubMed:17924679, PubMed:25288802)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (3)
Galactose catabolismGlycogen breakdown (glycogenolysis)Glycogen synthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1T

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
426.4 TPM
Coração - Ventrículo esquerdo
83.4 TPM
Aorta
80.8 TPM
Fígado
77.2 TPM
Coração - Átrio
72.0 TPM
OUTRAS DOENÇAS (1)
PGM1-congenital disorder of glycosylation
HGNC:8905UniProt:P36871
ALG11GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two G

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1P

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG11-congenital disorder of glycosylation
HGNC:32456UniProt:Q2TAA5
ALG2Programmed cell death protein 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium sensor that plays a key role in processes such as endoplasmic reticulum (ER)-Golgi vesicular transport, endosomal biogenesis or membrane repair. Acts as an adapter that bridges unrelated proteins or stabilizes weak protein-protein complexes in response to calcium: calcium-binding triggers exposure of apolar surface, promoting interaction with different sets of proteins thanks to 3 different hydrophobic pockets, leading to translocation to membranes (PubMed:20691033, PubMed:25667979). Inv

LOCALIZAÇÃO

Endoplasmic reticulum membraneCytoplasmic vesicle, COPII-coated vesicle membraneCytoplasmNucleusEndosome

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 14ALG2-congenital disorder of glycosylationobsolete congenital myasthenic syndromes with glycosylation defect
HGNC:23159UniProt:O75340
MGAT2Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an essential role in protein N-glycosylation. Catalyzes the transfer of N-acetylglucosamine (GlcNAc) onto the free terminal mannose moiety in the core structure of the nascent N-linked glycan chain, giving rise to the second branch in complex glycans

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
Maturation of spike proteinReactions specific to the complex N-glycan synthesis pathway
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2A

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
35.6 TPM
Linfócitos
34.8 TPM
Testículo
21.6 TPM
Cervix Ectocervix
11.6 TPM
Baço
11.4 TPM
OUTRAS DOENÇAS (1)
MGAT2-congenital disorder of glycosylation
HGNC:7045UniProt:Q10469
MAN1B1Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidaseCandidate gene tested inTolerante
FUNÇÃO

Involved in glycoprotein quality control targeting of misfolded glycoproteins for degradation. It primarily trims a single alpha-1,2-linked mannose residue from Man(9)GlcNAc(2) to produce Man(8)GlcNAc(2), but at high enzyme concentrations, as found in the ER quality control compartment (ERQC), it further trims the carbohydrates to Man(5-6)GlcNAc(2)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Maturation of spike proteinER Quality Control Compartment (ERQC)
MECANISMO DE DOENÇA

Rafiq syndrome

An autosomal recessive disorder characterized by variably impaired intellectual and motor development, a characteristic facial dysmorphism, truncal obesity, and hypotonia. The facial dysmorphism comprises prominent eyebrows with lateral thinning, downward-slanting palpebral fissures, bulbous tip of the nose, large ears, and a thin upper lip. Behavioral problems, including overeating, verbal and physical aggression, have been reported in some cases. Serum transferrin isoelectric focusing shows a type 2 pattern.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
63.3 TPM
Nervo tibial
51.8 TPM
Pituitária
49.8 TPM
Testículo
49.4 TPM
Cérebro - Hemisfério cerebelar
47.3 TPM
OUTRAS DOENÇAS (3)
Rafiq syndromeMAN1B1-congenital disorder of glycosylationautosomal recessive non-syndromic intellectual disability
HGNC:6823UniProt:Q9UKM7
RFT1Man(5)GlcNAc(2)-PP-dolichol translocation protein RFT1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Intramembrane glycolipid transporter that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses. Once assembled, the oligosaccharide is transferred from the lipid to nascent proteins by oligosaccharyltransferases. The asse

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1N

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
20.4 TPM
Linfócitos
17.5 TPM
Nervo tibial
13.7 TPM
Ovário
12.8 TPM
Testículo
12.2 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
RFT1-congenital disorder of glycosylation
HGNC:30220UniProt:Q96AA3
ALG8Dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, includi

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1H

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (3)
polycystic liver disease 3 with or without kidney cystsALG8-congenital disorder of glycosylationautosomal dominant polycystic liver disease
HGNC:23161UniProt:Q9BVK2
SSR4Translocon-associated protein subunit deltaDisease-causing germline mutation(s) inDesconhecido
FUNÇÃO

TRAP proteins are part of a complex whose function is to bind calcium to the ER membrane and thereby regulate the retention of ER resident proteins

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
SRP-dependent cotranslational protein targeting to membrane
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1Y

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
176.1 TPM
Glândula salivar
121.4 TPM
Pâncreas
97.1 TPM
Baço
89.5 TPM
Cervix Endocervix
84.7 TPM
OUTRAS DOENÇAS (1)
SSR4-congenital disorder of glycosylation
HGNC:11326UniProt:P51571
SLC39A8Metal cation symporter ZIP8Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Electroneutral divalent metal cation:bicarbonate symporter of the plasma membrane mediating the cellular uptake of zinc and manganese, two divalent metal cations important for development, tissue homeostasis and immunity (PubMed:12504855, PubMed:22898811, PubMed:23403290, PubMed:26637978, PubMed:29337306, PubMed:29453449). Transports an electroneutral complex composed of a divalent metal cation and two bicarbonate anions or alternatively a bicarbonate and a selenite anion (PubMed:27166256, PubMe

LOCALIZAÇÃO

Cell membraneLysosome membraneApical cell membraneBasolateral cell membrane

VIAS BIOLÓGICAS (1)
Zinc influx into cells by the SLC39 gene family
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2N

A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
85.8 TPM
Glândula salivar
36.1 TPM
Linfócitos
34.2 TPM
Adipose Visceral Omentum
25.0 TPM
Cervix Endocervix
19.0 TPM
OUTRAS DOENÇAS (1)
SLC39A8-CDG
HGNC:20862UniProt:Q9C0K1
TMEM165Putative divalent cation/proton antiporter TMEM165Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Putative divalent cation:proton antiporter that exchanges calcium or manganese ions for protons across the Golgi membrane. Mediates the reversible transport of calcium or manganese to the Golgi lumen driven by the proton gradient and possibly the membrane potential generated by V-ATPase. Provides calcium or manganese cofactors to resident Golgi enzymes and contributes to the maintenance of an acidic luminal Golgi pH required for proper functioning of the secretory pathway (By similarity) (PubMed

LOCALIZAÇÃO

Golgi apparatus membrane

MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2K

An autosomal recessive disorder with a variable phenotype. Affected individuals show psychomotor retardation and growth retardation, and most have short stature. Other features include dysmorphism, hypotonia, eye abnormalities, acquired microcephaly, hepatomegaly, and skeletal dysplasia. Congenital disorders of glycosylation are caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins and a wide variety of clinical features. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
62.1 TPM
Pulmão
58.4 TPM
Brain Spinal cord cervical c-1
58.3 TPM
Aorta
42.6 TPM
Vagina
40.8 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
TMEM165-congenital disorder of glycosylation
HGNC:30760UniProt:Q9HC07
STT3ADolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3ADisease-causing germline mutation(s) inRestrito
FUNÇÃO

Catalytic subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation (PubMed:19167329, PubMed:31296534, PubMed:31831667, PubMed:34653363, PubMed:38670073, PubMed:39509507). N-glycosylation occurs cotranslationally and the com

LOCALIZAÇÃO

Endoplasmic reticulumEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Maturation of spike proteinAsparagine N-linked glycosylationPD-L1(CD274) glycosylation and translocation to plasma membraneMaturation of DENV proteinsRegulation of CDH1 posttranslational processing and trafficking to plasma membrane
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1W, autosomal recessive

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
135.1 TPM
Linfócitos
70.2 TPM
Cervix Endocervix
65.8 TPM
Ovário
62.2 TPM
Útero
59.5 TPM
OUTRAS DOENÇAS (2)
STT3A-congenital disorder of glycosylationcongenital disorder of glycosylation, type Iw, autosomal dominant
HGNC:6172UniProt:P46977
SLC35A3UDP-N-acetylglucosamine transporterDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Transports diphosphate-N-acetylglucosamine (UDP-GlcNAc) from the cytosol into the lumen of the Golgi apparatus, functioning as an antiporter that exchanges UDP-N-acetyl-alpha-D-glucosamine for UMP (PubMed:10393322). May supply UDP-GlcNAc as substrate for Golgi-resident glycosyltransferases that generate highly branched, multiantennary complex N-glycans and keratan sulfate (PubMed:23766508, PubMed:34981577). However, the exact role of SLC35A3 still needs to be elucidated, it could be a member of

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Transport of nucleotide sugars
MECANISMO DE DOENÇA

Arthrogryposis, impaired intellectual development, and seizures

A disease characterized by arthrogryposis, intellectual disability, autism spectrum disorder, and epilepsy. Additional features include limb malformations, distal joint involvement, microcephaly, retromicrognathia, and general muscle hypotonia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon transverso
9.7 TPM
Glândula salivar
8.7 TPM
Intestino delgado
8.6 TPM
Tireoide
7.4 TPM
Vagina
7.3 TPM
OUTRAS DOENÇAS (1)
autism spectrum disorder - epilepsy - arthrogryposis syndrome
HGNC:11023UniProt:Q9Y2D2
ALG1Chitobiosyldiphosphodolichol beta-mannosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses.

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1K

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG1-congenital disorder of glycosylation
HGNC:18294UniProt:Q9BT22
ALG6Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including t

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1C

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG6-congenital disorder of glycosylation 1C
HGNC:23157UniProt:Q9Y672
ALG13UDP-N-acetylglucosamine transferase subunit ALG13Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalytic subunit of the UDP-N-acetylglucosamine transferase complex that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, includi

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent proteinDefective ALG14 causes ALG14-CMS
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 36

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. Some DEE36 patients may present with an abnormal isoelectric focusing of serum transferrin, consistent with a diagnostic classification of congenital disorder of glycosylation type I. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 36non-syndromic X-linked intellectual disability
HGNC:30881UniProt:Q9NP73
PMM2Phosphomannomutase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the synthesis of the GDP-mannose and dolichol-phosphate-mannose required for a number of critical mannosyl transfer reactions

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1A

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1A is an autosomal recessive disorder characterized by a severe encephalopathy with axial hypotonia, abnormal eye movement, and pronounced psychomotor retardation, as well as peripheral neuropathy, cerebellar hypoplasia, and retinitis pigmentosa. Patients show a peculiar distribution of subcutaneous fat, nipple retraction, and hypogonadism.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
31.1 TPM
Linfócitos
27.3 TPM
Esôfago - Mucosa
15.7 TPM
Glândula salivar
15.1 TPM
Cólon transverso
11.8 TPM
OUTRAS DOENÇAS (1)
PMM2-congenital disorder of glycosylation
HGNC:9115UniProt:O15305
ALG12Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses.

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1G

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
ALG12-congenital disorder of glycosylation
HGNC:19358UniProt:Q9BV10
MPIMannose-6-phosphate isomeraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Isomerase that catalyzes the interconversion of fructose-6-P and mannose-6-P and has a critical role in the supply of D-mannose derivatives required for many eukaryotic glycosylation reactions

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1B

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1B is clinically characterized by protein-losing enteropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
31.8 TPM
Glândula adrenal
25.9 TPM
Ovário
23.0 TPM
Fibroblastos
23.0 TPM
Testículo
21.5 TPM
OUTRAS DOENÇAS (1)
MPI-congenital disorder of glycosylation
HGNC:7216UniProt:P34949
DDOSTDolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunitDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation (PubMed:31831667). N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (6)
Maturation of spike proteinAsparagine N-linked glycosylationPD-L1(CD274) glycosylation and translocation to plasma membraneMaturation of DENV proteinsRegulation of CDH1 posttranslational processing and trafficking to plasma membrane
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1R

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
426.3 TPM
Linfócitos
248.3 TPM
Ovário
225.6 TPM
Baço
223.2 TPM
Tireoide
195.4 TPM
OUTRAS DOENÇAS (1)
DDOST-congenital disorder of glycosylation
HGNC:2728UniProt:P39656

Medicamentos e terapias

EPALRESTATPhase 3

Mecanismo: Aldose reductase inhibitor

ACETAZOLAMIDEPhase 2

Mecanismo: Carbonic anhydrase XII inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

252 variantes patogênicas registradas no ClinVar.

🧬 ALG3: NM_005787.6(ALG3):c.606-2A>C ()
🧬 ALG3: NM_005787.6(ALG3):c.859C>T (p.Arg287Ter) ()
🧬 ALG3: GRCh37/hg19 3q22.1-29(chr3:132561657-197851986)x3 ()
🧬 ALG3: NM_005787.6(ALG3):c.452C>T (p.Pro151Leu) ()
🧬 ALG3: NM_005787.6(ALG3):c.1162del (p.Val388fs) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

38 vias biológicas associadas aos genes desta condição.

Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein Defective ALG3 causes CDG-1d Defective MOGS causes CDG-2b N-glycan trimming in the ER and Calnexin/Calreticulin cycle Maturation of spike protein Maturation of spike protein Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Defective ALG9 causes CDG-1l Defective DPAGT1 causes CDG-1j, CMSTA2 Asparagine N-linked glycosylation Maturation of DENV proteins Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition PD-L1(CD274) glycosylation and translocation to plasma membrane Glycogen synthesis Defective PGM1 causes PGM1-CDG Neutrophil degranulation Glycogen breakdown (glycogenolysis) Galactose catabolism Defective ALG11 causes CDG-1p Defective ALG2 causes CDG-1i Defective ALG14 causes ALG14-CMS Defective MGAT2 causes CDG-2a Reactions specific to the complex N-glycan synthesis pathway Defective MAN1B1 causes MRT15 ER Quality Control Compartment (ERQC) Defective RFT1 causes CDG-1n Defective ALG8 causes CDG-1h SRP-dependent cotranslational protein targeting to membrane Zinc influx into cells by the SLC39 gene family Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS) Transport of nucleotide sugars Defective ALG1 causes CDG-1k Defective ALG6 causes CDG-1c Defective PMM2 causes PMM2-CDG Synthesis of GDP-mannose Defective ALG12 causes CDG-1g Defective MPI causes MPI-CDG Advanced glycosylation endproduct receptor signaling

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 22
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 2 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Alteração da proteína N-glicosilação

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Alteração da proteína N-glicosilação.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Alteração da proteína N-glicosilação

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. PGM1 deficiency: Substrate use during exercise and effect of treatment with galactose.
    Neuromuscular disorders : NMD· 2017· PMID 28190645mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:309347(Orphanet)
  2. MONDO:0017740(MONDO)
  3. GARD:21335(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55787316(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Alteração da proteína N-glicosilação

ORPHA:309347 · MONDO:0017740
CID-11
Medicamentos
2 registrados
MedGen
UMLS
C5681044
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades